| Literature DB >> 18412971 |
Silvia Selleri1, Sara Deola, Zoltan Pos, Ping Jin, Andrea Worschech, Stefanie L Slezak, Cristiano Rumio, Monica C Panelli, Dragan Maric, David F Stroncek, Ena Wang, Francesco M Marincola.
Abstract
BACKGROUND: Upon Ag-activation cytotoxic T cells (CTLs) produce IFN-gamma GM-CSF and TNF-alpha, which deliver simultaneously pro-apoptotic and pro-inflammatory signals to the surrounding microenvironment. Whether this secretion affects in an autocrine loop the CTLs themselves is unknown.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18412971 PMCID: PMC2330025 DOI: 10.1186/1479-5876-6-17
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Figure 1Gene expression profile: comparison between antigen specific and convivial non specific CD8+ T cells. A) representative example of in vitro expansion of Flu M1:58-66-specific CD8 T cells in the presence of 300 IU/IL-2 and purity of the sorting procedure by high speed flow cytometry (FACSVantage SE); B) multiple dimensional scaling representing the four populations of CD8 T cells based on the complete data set of 16,726 cDNA clones. CD8 expressing, CSFEhigh, Flu/tHLA negative T cells (non Flu specific) are referred to as IL-2 while CD8 expressing, CSFElow, Flu/tHLA positive T cells are referred to as IL-2+Flu; C) Venn diagram displaying the extent of overlap between genes differentially expressed by Flu-specific and non Flu-specific CTLs from the same culture compared to quiescent CD8-expressing T cells; D) Multiple dimensional scaling plot representing Flu-specific and convivial CD8 T cells distribution using the complete data set of 16,726 cDNA clones.
Difference in the transcriptional pattern of quiescent compared to stimulated CD8 T cells
| Permutation Test (p-value) | ||
| 6,692 ( | 0 | |
| 5,527 ( | 0 | |
| 4, 702 ( | 0 | |
| 4,893 ( | 0 | |
| 5, 859 ( | 0 | |
| 1,727 (t test), n = 12 | 0 |
Ex vivo refers to the transcriptional analysis of freshly isolated and processed CD8 positive T cells; CD8 T cells were also sorted by high speed FACS sorter from PBMC from HLA-A*0201 expressing normal donors that had been cultured for 7 days in the presence of 300 IU IL-2 following stimulation with the Flu M1:58-66 peptide according to their level of CFSE and Flu/tHLA staining. CD8 expressing, CSFEhigh, Flu/tHLA negative T cells (non Flu specific) are referred to as IL-2 while CD8 expressing, CSFElow, Flu/tHLA positive T cells are referred to as IL-2+Flu
| Immune Genes Up-regulated in Flu-specific CD8 T cells | Immune GenesUp-regulated in convivial CD8 T cells | ||||
| Symbol | Δ | Symbol | Δ | ||
| IFNG | Interferon gamma | 8.64 | IFNGR2 | interferon-γ receptor 2 | 7.73 |
| CSF2 | Colony stimulating factor 2 | 7.55 | GZMK | granzyme K | 7.12 |
| CCL3 | Chemokine (C-C motif) ligand 3 | 7.13 | XCL1 | Chemokine (C motif) ligand 1 | 6.39 |
| CD38 | CD38 | 6.99 | SOCS3 | STAT induced STAT inhibitor-3 = CIS3 | 5.02 |
| CD80 | CD80 = B7-1 | 6.90 | CX3CR1 | Chemokine (C-X3-C motif) receptor 1 | 4.91 |
| CSF2RB | Colony stimulating factor 2 receptor, beta | 5.58 | CCR7 | Chemokine (C-C motif) receptor 7 | 4.58 |
| APOA2 | Apolipoprotein A-II | 5.13 | TIMP2 | TIMP metallopeptidase inhibitor 2 | 4.53 |
| GZMB | Granzyme B | 4.72 | IL24 | interleukin 24 | 4.47 |
| CSF2RB | GM-CSF/IL-5/IL-3 receptor common beta chain | 3.64 | PF4 | Platelet factor 4 (chemokine) ligand 4 | 4.29 |
| GNLY | Granulysin | 3.62 | LY86 | Lymphocyte antigen 86 | 4.26 |
| CCL4 | MIP-1 beta | 3.54 | ITGA6 | CD49F = Integrin alpha 6 | 3.75 |
| CD86 | CD86 = B7.2 | 3.54 | PECAM1 | platelet/endothelial cell adhesion molecule (CD31) | 3.37 |
| CD226 | adhesion molecule DNAM-1 | 3.51 | LY9 | lymphocyte antigen 9 | 2.97 |
| CXCR6 | Chemokine (C-X-C motif) receptor 6 | 3.32 | JAK1 | Janus kinase 1 | 2.68 |
| ITGA2 | Integrin, alpha 2 (CD49B) | 3.30 | TNFSF13 | Tumor necrosis factor superfamily13 | 2.68 |
| DUSP16 | Dual specificity phosphatase 16 | 2.91 | IL8 | Interleukin 8 | 2.55 |
| IL1RAP | Interleukin 1 receptor accessory protein | 2.37 | TIMP1 | tissue inhibitor of metalloproteinase 1 | 2.47 |
| CCR1 | C-C chemokine receptor 1 | 2.30 | CISH | Cytokine inducible SH2-containing protein | 2.46 |
| DUSP5 | dual specificity phosphatase 5 | 2.27 | CD163 | CD163 | 2.39 |
| ITGB7 | CD103 beta = Integrin beta 7 | 2.22 | CTSS | Cathepsin S | 2.17 |
| ICOS | inducible T-cell co-stimulator | 2.22 | GABBR1 | GABA-BR1a (hGB1a) receptor | 2.16 |
| DUSP10 | Dual specificity phosphatase 10 | 1.88 | SELL | CD62L = L-selectin | 2.16 |
| GZMA | Granzyme A | 1.43 | CXCL1 | GRO1 = GRO α | 2.15 |
| CTSD | Cathepsin D | 1.43 | CSF3R | G-CSF receptor | 2.14 |
| ENTPD1 | CD39 | 1.31 | GRN | Granulin | 2.06 |
| CCL18 | PARC | 1.10 | CD33 | CD33 molecule | 2.04 |
| CD58 | LFA-3 | 1.10 | IL11RA | IL-11 receptor α chain | 1.90 |
| IL2RB | IL-2 receptor beta chain | 1.07 | CXCR4 | chemokine (C-X-C motif), receptor 4 (fusin) | 1.85 |
| CCL2 | MCP-1 | 1.06 | IL7R | IL-7 receptor α chain | 1.58 |
| CTSC | Cathepsin C | 0.98 | VEGFB | Vascular endothelial growth factor B | 1.55 |
| IL2RA | interleukin 2 receptor, alpha | 0.92 | IL4R | IL-4 receptor α chain | 1.45 |
| STAT1 | STAT1 | 1.39 | |||
| IFNGR1 | interferon-gamma receptor α chain | 1.33 |
Figure 2Gene expression profile: comparison between antigen specific and convivial non specific CD8+ T cells. A) Selection of genes among 1,727 genes differentially expressed between Flu-specific (green bar) and convivial (red bar) CD8 T cells at a t test p2-value < 0.001 whose annotation includes the word "interferon". The table displays the gene symbol, its name and the level of differential expression (Δ) as the CY5/CY3 ratio of fly-specific versus convivial in green and vice versa in red.
Figure 3CD131 expression following IVS with Flu M1:58-66 peptide. Expression of CD131 (GMCSF receptor β chain) in Flu M1:58-66-activated (tHLA/Flu +) and convivial (tHLA/Flu-) CTLs (corresponding to R4 and R7 in Figure 1) after 6 (A) and 12 (B) days of IVS of HLA-A*0201 expressing PBMCs in the presence of 300 IU/ml of IL-2; C – Fold increase (FI) of HLA-A*0201 PBMCs exposed to IVS with Flu M1:58-66 peptide (Flu) plus exogenous administration every other day of IL-2 (300 IU/ml), GMCSF (1,000 U/ml), IFN-γ (500 IU/ml) or a combination of them for 6 (white bars) or 12 (black bars) days. Data are presented as average ± standard error from the mean of 5 experiments performed in PBMCs from 5 different donors; * and ** = paired Student t test p-value ≤ 0.05 and ≤ 0.01 respectively between comparing FI in individuals experimental groups with the FI in respective PBMC populations stimulated only with Flu; The difference in significance between Flu+IL-2+GMCSF FI at day 12 and that of Flu+IL-2 and Flu+IL-2+IFN-γ are outlined specifically in the graph.